Opthea Ltd — Board/Management Information 2013

Nov 28, 2013

==> picture [211 x 55] intentionally omitted <==

ASX and Media Release

29 November 2013

Director Resignation

Circadian Technologies Limited (ASX : CIR) advises that Mr Don Clarke has resigned and will not seek re-election at the company’s Annual General Meeting to be held today.

The board would like to express its sincere appreciation to Mr Clarke for his contribution over the past eight years as a Non-Executive Director and as Chair of the Remuneration Committee.

Further enquiries

Dominique Fisher Board Chair Tel: +61 (0) 3 9826 0399

About Circadian Technologies Limited

Circadian (ASX:CIR; OTCQX:CKDXY)) is a biologics drug developer focusing on cancer, cancer related and ophthalmic disease therapies. It controls exclusive worldwide rights to a significant intellectual property portfolio around Vascular Endothelial Growth Factor (VEGF)-C and -D. The applications for the VEGF technology, which functions in regulating blood and lymphatic vessel growth, are substantial and broad. Circadian’s internal product development programs are primarily focused on developing VGX-100 (a human antibody against VEGF-C) as a treatment for lymphedema resulting from breast cancer treatment and solid tumours, in particular glioblastoma and colorectal cancer, as well as developing VGX-300 (soluble VEGFR-3) for ‘back of the eye’ disease such as wet Age Related Macular Degeneration. Circadian has also licensed rights to some parts of its intellectual property portfolio for the development of other products to ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, including the anti-lymphatic antibody-based drug IMC-3C5 targeting VEGFR-3.

Suite 0403 Level 4/650 Chapel Street South Yarra 3141 Victoria Australia T +61 (3) 9826 0399 F +61 (3) 9824 0083 www.circadian.com.au

ABN 32 006 340 567